Inhibiting specific phosphodiesterase (PDE) enzymes to augment cyclic guanosine monophosphate (cGMP)‐dependent signaling is a cornerstone of therapy in pulmonary arterial hypertension (PAH) (Archer & Michelakis, 2009). Here, ALDH7A1 is linked to pulmonary arterial hypertension.